All news

TD Cowen keeps Buy on Regeneron with $980 target

Alpha Vantage · TradingView · · AI-summarised by FinFlash

TD Cowen has reaffirmed its Buy rating on Regeneron Pharmaceuticals (REGN) and set a price target of $980.00, representing a 21.4% upside from its Oct 20 closing price. The analyst note highlights Regeneron's strong product portfolio, including Eylea, Dupixent, and Libtayo, as well as a positive financial outlook driven by updated sales estimates for Eylea HD and increased collaboration revenue.

Read original source

REGN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.